News
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
Valbiotis meldet bedeutenden Erfolg der klinischen Phase-II-Studie HEART: die patentgeschützte pflanzenbasierte aktive Substanz TOTUM•070 zeigt Wirksamkeit gegen Hypercholesterinämie, einen kardiovaskulären Risikofaktor
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechsel- und
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
Pfizer Inc. (NYSE: PFE) today shared data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) study evaluating the use of PAXLOVID™ (nirmatrelvir
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610)
LivaNova Elects Peter Wilver to Board of Directors
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: MicroVision to Showcase its Automotive Lidar Sensor at ADAS & Automotive Technology Expo in Stuttgart, Germany
Humana to Donate Downtown Louisville Office Building to UofL
Humana Inc. (NYSE: HUM) today announced that it will donate an office building in Downtown Louisville to the University of Louisville (UofL) in support of the activities of UofL’s Health Equity
Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal Year 2022 Conference Call To Be Held on June 27, 2022
Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!
Come chill with us! This week is Diabetes Awareness Week and DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (rt-CGM) for people with diabetes, is honouring
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
DGAP-News: Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX)
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: w
Pfizer Completes Acquisition of ReViral
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
Annual General Meeting of Kuros Biosciences approves all resolutions
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022